These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Acute reversible neurological deficit following intrathecal chemotherapy.
    Author: Dunkelman H, Earl HM, Twelves C.
    Journal: Cancer Chemother Pharmacol; 1991; 27(4):329-30. PubMed ID: 1998991.
    Abstract:
    We report on two patients with non-Hodgkin's lymphoma (NHL) who developed reversible, short-lived neurological deficit following intrathecal (i.t.) chemotherapy. One patient received i.t. methotrexate for treatment of meningeal disease, and the other received i.t. methotrexate with cytosine arabinoside (ara-C) and hydrocortisone as central nervous system (CNS) prophylaxis. Although transient paresis following i.t. chemotherapy has previously been reported, it has been attributed to the preservatives contained in the diluents. Our two patients, however, received preservative-free solutions.
    [Abstract] [Full Text] [Related] [New Search]